Cargando…
Shorter Time to Discontinuation Due to Treatment Failure in People Living with HIV Switched to Dolutegravir Plus Either Rilpivirine or Lamivudine Compared with Integrase Inhibitor-Based Triple Therapy in a Large Spanish Cohort
INTRODUCTION: Standard therapy for HIV treatment has consisted of two nucleoside analogue reverse transcriptase inhibitors (NRTI) paired with a third agent. Use of two-drug regimens (2DR) has been considered for selected patients in part to avoid toxicities associated with the use of NRTIs. This stu...
Autores principales: | Teira, Ramón, Diaz-Cuervo, Helena, Aragão, Filipa, Castaño, Manuel, Romero, Alberto, Roca, Bernardino, Montero, Marta, Galindo, Maria José, Muñoz-Sánchez, Maria Jose, Espinosa, Nuria, Peraire, Joaquim, Martínez, Elisa, de la Fuente, Belén, Domingo, Pere, Deig, Elisabeth, Merino, María Dolores, Geijo, Paloma, Estrada, Vicente, Sepúlveda, María Antonia, García, Josefina, Berenguer, Juan, Currán, Adriá |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124284/ https://www.ncbi.nlm.nih.gov/pubmed/35399147 http://dx.doi.org/10.1007/s40121-022-00630-y |
Ejemplares similares
-
Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV
por: Dueñas-Gutiérrez, Carlos, et al.
Publicado: (2023) -
Dolutegravir–lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study
por: Cahn, Pedro, et al.
Publicado: (2017) -
Dolutegravir/rilpivirine for the treatment of HIV-1 infection
por: Dowers, Ellen, et al.
Publicado: (2018) -
Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice
por: Suárez-García, Inés, et al.
Publicado: (2023) -
Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study
por: Troya, Jesús, et al.
Publicado: (2022)